CompletedPhase 1NCT01174888
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Studying Acute myeloid leukaemia with myelodysplasia-related features
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alison Walker
- Principal Investigator
- Alison Walker, MDThe Ohio State University James Cancer Hospital
- Intervention
- midostaurin(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2016
Study locations (1)
- The Ohio State University Medical Center, Columbus, Ohio, United States
Collaborators
Novartis · Millennium Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01174888 on ClinicalTrials.govOther trials for Acute myeloid leukaemia with myelodysplasia-related features
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04802161Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesNational Cancer Institute (NCI)
- RECRUITINGNCT01210274Characterization of the Mechanisms of Resistance to AzacitidineCentre Hospitalier Universitaire de Nice
See all trials for Acute myeloid leukaemia with myelodysplasia-related features →